Abstract:Introduction After decades of stumbling clinical development, the first gene therapies for haemophilia A and B have been commercialized and have normalized factor (F)VIII and factor (F)IX levels in some individuals in the long term. Several other clinical programs testing adeno‐associated viral (AAV) vector gene therapy are at various stages of clinical testing. Discussion Multiyear follow‐up in phase 1/2 and 3 studies showed long‐term and sometimes curative but widely variable and unpredictable efficacy. Liver toxicities, mostly low‐grade, occur in the 1st year in at least some individuals in all haemophilia A and B trials and are poorly understood. Wide variability and unpredictability of outcome and slow decline of FVIII levels are a major disadvantage because immune responses to AAV vectors preclude repeat dosing, which otherwise could improve suboptimal or restore declining expression, while overexpression may predispose to thrombosis. Long‐term safety outcomes will need lifelong monitoring because AAV vectors infused at high doses integrate into chromosomes at rates that raise questions about potential oncogenicity and necessitate vigilance. Alternative gene transfer systems employing gene editing and/or non‐viral vectors are under development and promise to overcome some limitations of the current state of the art for both haemophilia A and B. Conclusions AAV gene therapies for haemophilia have now become new treatment options but not universal cures. AAV is a powerful but imperfect gene transfer platform. Biobetter FVIII transgenes may help solve some problems plaguing gene therapy for haemophilia A. Addressing variability and unpredictability of efficacy, and delivery of gene therapy to ineligible patient subgroups may require different gene transfer systems, most of which are not ready for clinical translation yet but bring innovations needed to overcome the current limitations of gene therapy.

[Advances in AAV-CRISPR/Cas9-Mediated Hemophilia A Gene Therapy --Review]

Gene Therapy for Hemophilia B in Immature Mice Using ScAAV-DJ/8-LP1-hFIXco Vector

Recent Advances in Gene Therapy for Hemophilia: Projecting the Perspectives

CRISPR/Cas9-Mediated in vivo Genetic Correction in a Mouse Model of Hemophilia A

Gene therapy for hemophilia: looking beyond factor expression

[Social Security and district psychiatry].

CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice

Gene Therapy for Hemophilia B Mediated by Recombinant Adeno-Associated Viral Vector with Hfixr338a,a High Catalytic Activity Mutation of Human Coagulation Factor IX

Hemophilia Healing with AAV: Navigating the Frontier of Gene Therapy

Gene Therapy for Hemophilia B Mice with Scaav8-Lp1-hfix

In vivo LNP-CRISPR Approaches for the Treatment of Hemophilia

Hemophilia Gene Therapy: New Development from Bench to Bed Side.

Targeted genome engineering based on CRISPR/Cas9 system to enhance FVIII expression in vitro

Targeted Gene Insertion: The Cutting Edge of CRISPR Drug Development with Hemophilia as a Highlight

Current and emerging Gene Therapies for Haemophilia A and B

AAV mediated gene therapy for haemophilia B: From the early attempts to modern trials

Hemophilia Gene Therapy: from Bench to Bed Side.

CRISPR/Cas9-mediated Somatic and Germline Gene Correction to Restore Hemostasis in Hemophilia B Mice

Research Progress of for Non-viral Gene Therapy for Hemophilia

Gene Therapy for Hemophilia B: Achievements, Open Issues, and Perspectives

Characteristics of BAY 2599023 in the Current Treatment Landscape of Hemophilia A Gene Therapy